Epic Games launched its mobile store for iPhone and iPad in the EU last year, and it has since established a popular program of weekly game giveaways. This week, it is making one of the most awarded ...

Scientists have captured a never-before-seen, high-resolution look at influenza’s stealthy invasion of human cells, revealing that the cells aren’t just helpless victims. Using a groundbreaking ...

Texas A&M researchers found a way to make stem cells produce double the normal number of mitochondria using nanoflower particles. These energized stem cells then transfer their surplus “power packs” ...

Biomedical researchers at Texas A&M University may have discovered a way to stop or even reverse the decline of cellular energy production—a finding that could have revolutionary effects across ...

Clearing aged cells from blood vessels could help reduce inflammation, improve blood sugar levels and counter insulin resistance, a mouse study finds. When you purchase through links on our site, we ...

An elite Iranian military unit plotted to assassinate the Israeli ambassador to Mexico, according to a US official familiar with the matter. The plan, hatched by the Iranian Revolutionary Guard Corps’ ...

CSL Seqirus, the vaccine unit of Australian biotech CSL, has signed a pact to provide Saudi Arabia with cell-based influenza shots and help establish its production in-country. The move forms part of ...

Galapagos (NASDAQ:GLPG) ADRs dropped ~13% in the premarket on Tuesday after the Belgian biotech announced plans to wind down its cell therapy business, impacting roughly 365 employees in Europe, the U ...

Galapagos is planning to wind down its cell therapy business, completing a whiplash change that saw the biotech go from focusing on the modality to ditching it in six months. Belgium-based Galapagos ...

Oct 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday.

Ozempic maker Novo Nordisk (NVO) is closing its cell therapy division as part of a major restructuring drive initiated under the company’s new CEO, Mike Doustdar, Bloomberg News reported on Thursday, ...

Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the ...